Research has uncovered genetic mutations that can be present in 60% of Nsclc-type lung cancers; and for these it is potentially possible to set up targeted therapies in 4 out of 10 cases, capable of improving the quality and life expectancy of patients. This is why an increasingly innovative and effective diagnosis makes a difference in the therapeutic approach of patients with lung cancer. Massimo Di Maio, national secretary of AIOM, and director of the Oncology of the Mauriziano hospital in Turin, explains why lung cancers are on the rise especially among women and how molecular diagnosis can change the history of the disease.
Molecular diagnosis: this is how lung cancer treatment changes
